Paroxysmal Nocturnal Hemoglobinuria (PNH)

Gerard Socie, MD

Institution
Hospital St. Louis
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Graft Versus Host Disease (GVHD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Gerard Socié, MD, PhD, is the head of the hematology department at Hospital Saint-Louis, APHP. Gerard Socié has a research appointment at the Institut Pasteur -APHP with Dr. Lars Rogge. His main fields of expertise are transplantation (GvHD), aplastic anemia, PNH and Fanconi Anemia. Dr. Socié discusses the diagnosis, treatment and prognosis of PNH in this pre-recorded session.

Kanwaldeep Mallhi, MD

Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant.

Sioban Keel, MD

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Sioban Keel, M.D., is a board certified hematologist at SCCA and a UW associate professor of Hematology and Medicine. Dr. Keel believes that excellent medical care requires a combination of up-to-date knowledge and compassionate, individualized patient care. She recognizes that excellent care requires physicians who communicate effectively with and educate each patient so that they understand their condition and can be a partner in determining the best treatment plan. Dr. Keel earned her M.D. at the University of Minnesota. Her clinical and research interests include benign red blood cell

Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Original Publication Date
Article Source
External Web Content
– With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH – – Approval based on interim results from Phase 3 study showing ULTOMIRIS demonstrated complete terminal complement inhibition through 26 weeks – BOSTON…

Living with PNH: A Patient Panel Discussion

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Leigh Clark
Patient panel discussions are a chance to meet some of the inspiring patients, caregivers and parents who are dealing with a bone marrow failure disease. Panel discussions are a bit different from our regular educational webinars so please plan to participate via the Q & A window…

Pegcetacoplan Superior to Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Original Publication Date
Article Source
External Web Content
Pegcetacoplan was superior to eculizumab in improving outcomes in patients with paroxysmal nocturnal hemoglobinuria (PNH) according to a recent study published in the New England Journal of Medicine. PNH is a rare, acquired hematologic disease that causes fatigue, increased risk…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.